Melanoma Vaccine from NeoVox Shows Anti-Tumor Response Four Years Later

Source: Clinical OMICs, January 2021

In encouraging news regarding melanoma therapy, researchers found that a personalized vaccine continues to keep cancer cells in check four years after patients received it.

In a Phase 1 study among eight patients with advanced melanoma who received the NeoVax vaccine, after a median of four years, all of the patients were alive. Six patients had no signs of active disease.

Further, studies of patients’ T cells revealed they were still active against their originally targeted proteins on melanoma cells but also recognized others.

READ THE ORIGINAL FULL ARTICLE